Introduction: The therapeutic approach in multiple sclerosis (MS) is radically changing. From the early stages of MS, a hard-hitting approach to treatment is taken with strong anti-inflammatory drugs being a possible therapeutic option. Areas covered: The concept of induction therapy is emerging in the MS therapeutic scenario. Expert opinion: Not all the MS licensed drugs are suitable candidates for induction therapy. The upcoming challenge will be to identify, after a careful and individual assessment of risk/benefit ratio, the ideal patient who is a candidate to such aggressive therapeutic approach.
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion
D’Amico, EmanueleConceptualization
;
2017-01-01
Abstract
Introduction: The therapeutic approach in multiple sclerosis (MS) is radically changing. From the early stages of MS, a hard-hitting approach to treatment is taken with strong anti-inflammatory drugs being a possible therapeutic option. Areas covered: The concept of induction therapy is emerging in the MS therapeutic scenario. Expert opinion: Not all the MS licensed drugs are suitable candidates for induction therapy. The upcoming challenge will be to identify, after a careful and individual assessment of risk/benefit ratio, the ideal patient who is a candidate to such aggressive therapeutic approach.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Exp. Opin. Pharmacoth. 2017.pdf
solo gestori archivio
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.81 MB
Formato
Adobe PDF
|
1.81 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.